These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38905051)

  • 1. Citicoline: A Cholinergic Precursor with a Pivotal Role in Dementia and Alzheimer's Disease.
    Gareri P; Cotroneo AM; Montella R; Gaglianone M; Putignano S
    J Alzheimers Dis; 2024; 100(2):725-733. PubMed ID: 38905051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study.
    Gareri P; Castagna A; Cotroneo AM; Putignano D; Conforti R; Santamaria F; Marino S; Putignano S
    J Alzheimers Dis; 2017; 56(2):557-565. PubMed ID: 28035929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer's Disease.
    Castagna A; Fabbo A; Manzo C; Lacava R; Ruberto C; Ruotolo G
    J Alzheimers Dis; 2021; 79(4):1509-1515. PubMed ID: 33459645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease.
    Castagna A; Manzo C; Fabbo A; Lacava R; Ruberto C; Ruotolo G
    Clin Drug Investig; 2021 Feb; 41(2):177-182. PubMed ID: 33484469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Overview of Combination Treatment with Citicoline in Dementia.
    Gareri P; Veronese N; Cotroneo AM
    Rev Recent Clin Trials; 2022; 17(1):4-8. PubMed ID: 34939548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study.
    Castagna A; Cotroneo AM; Ruotolo G; Gareri P
    Clin Drug Investig; 2016 Dec; 36(12):1059-1065. PubMed ID: 27587069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia.
    Gareri P; Cotroneo AM; Orsitto G; Putignano S
    Arch Gerontol Geriatr; 2020; 89():104073. PubMed ID: 32447126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Importance of Citicoline in Combined Treatment in Dementia: What did the Citimem Study Teach us?
    Gareri P; Cotroneo AM; Orsitto G; Putignano S
    Rev Recent Clin Trials; 2021; 16(2):126-130. PubMed ID: 33243132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
    Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
    J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study.
    Cotroneo AM; Castagna A; Putignano S; Lacava R; Fantò F; Monteleone F; Rocca F; Malara A; Gareri P
    Clin Interv Aging; 2013; 8():131-7. PubMed ID: 23403474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Citicoline as an Adjunct Treatment for Alzheimer's Disease: A Systematic Review.
    Piamonte BLC; Espiritu AI; Anlacan VMM
    J Alzheimers Dis; 2020; 76(2):725-732. PubMed ID: 32538854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
    Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine.
    Desmidt T; Hommet C; Camus V
    Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis.
    Glinz D; Gloy VL; Monsch AU; Kressig RW; Patel C; McCord KA; Ademi Z; Tomonaga Y; Schwenkglenks M; Bucher HC; Raatz H
    Swiss Med Wkly; 2019 Jun; 149():w20093. PubMed ID: 31269225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.